Effects of siRNA Combining TGF-β1 Silencing and RIG-I Activation in Pancreas Cancer 

Get Permission

Dysregulation of TGF-β signaling promotes tumor growth, invasion, metastasis, and a potent immunosuppressive network in pancreas cancer. A strategy for disrupting the tumor-promoting pathway is the silencing of TGF-β by use of small-interfering (si) RNA. Ellermeier and colleagues found that the introduction of a triphosphate group at the 5′ end of siRNA (ppp-siRNA) allowed gene silencing to be combined with immune activation via the cytosolic helicase retinoic acid-inducible gene I (RIG-I), a ubiquitously expressed receptor that recognizes viral RNA.

The investigators validated RIG-I as a therapeutic target by showing that its activation in pancreatic carcinoma cells induced interferon regulatory transcription factor-3 phosphorylation, production of type I interferon, production of chemokine CXCL10, and caspase-9–mediated tumor cell apoptosis. They then generated a bifunctional ppp-siRNA that combined RIG-I activation with gene silencing of TGF-β(ppp-TGF-β) and assessed its effects in the orthotopic Panc02 mouse model of pancreatic cancer.

Injection of ppp-TGF-β resulted in reduced systemic and tumor-associated TGF-β levels, high levels of type I interferon and CXCL10 in serum and tumor tissue, increased systemic immune cell activation, and marked tumor cell apoptosis in vivo. Treatment with ppp-TGF-β in mice with established tumors significantly prolonged survival compared with ppp-RNA or TGF-β siRNA treatment alone. Recruitment of activated CD8+ T cells to the tumor was observed along with a reduced frequency of CD11bGr-1+ myeloid cells, with therapeutic efficacy being dependent on levels of CD8+ T cells.

The investigators concluded, “[C]ombining TGF-β gene silencing with RIG-I signaling confers potent antitumor efficacy against pancreatic cancer by breaking tumor-induced CD8+ T cell suppression.” ■

Ellermeier J, Wei J, Duewell P, et al: Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 73:1709-1720, 2013.

Lab Notes is compiled and written for The ASCO Post by Matthew Stenger.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.